- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00338026
A Phase I Study of ECO-4601 in Patients With Advanced Cancer
10. juli 2008 opdateret af: Thallion Pharmaceuticals
A Phase I, Dose Finding, Pharmacokinetic, and Safety Study of Continuous IV Infusion of ECO-4601 in Patients With Advanced Cancer Including an Extension Portion to Obtain Safety Data at the Highest Tolerable Dose
The purpose of this study was to determine the maximum tolerated dose (MTD) and the recommended dose for future studies of ECO-4601 administered as a continuous IV infusion for 14 days with 7 days recovery (21 day cycle) in patients with histologically confirmed solid tumors (high grade glioma, colorectal, lung, breast, ovarian, pancreatic and prostate).
This study was also designed to determine the clinical pharmacokinetic profile, safety of multiple cycles of administration, and document the antitumor activity of ECO-4601.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
26
Fase
- Fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V 2H1
- Hopital Charles LeMoyne
-
Montreal, Quebec, Canada, H3T 1E2
- Sir Mortimer B. Davis Jewish General Hospital
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Informed about the study and consent to participate in the study
- Clinically or radiologically documented advanced solid malignancy for which no standard therapy is available, or which has failed standard therapy
- Patients with the following solid tumors: high grade glioma, colorectal, prostate, pancreatic, lung, ovarian and breast carcinoma
- Age ≥ 18 years of age
- ECOG ≤ 2
- Laboratory hematology and biochemistry protocol test result abnormalities ≤ Grade 1, graded using NCI CTCAE version 3.0
- Patients with no chemotherapy during the 4 weeks preceding patients' first dose of ECO-4601 (day 1, cycle 1)
- No other anticancer treatment during the study
- Patients can be receiving stable or decreasing dose of steroids within 2 weeks prior to patient's signature of the informed consent
- Patients must be accessible for treatment and follow-up. Patients registered on this trial must be treated and followed at the participating centre
Previous Therapy
- Hormonal therapy: Patients may have had prior hormonal therapy provided it is discontinued upon ICF signature
- Radiation: Patients may have had prior radiation therapy. Patients must have recovered from the acute toxic effects of radiotherapy
- Previous surgery: Previous surgery is permitted provided that at least 2 weeks have elapsed between major surgery (non-biopsy) and ICF signature
Exclusion Criteria:
- Patients with brain metastases
- Unlikely to comply with protocol or difficulty to understand the purpose of the study
- Life expectancy < 12 weeks
- Clinically significant co-morbid disease, e.g. renal failure, ischemic vascular disease, uncontrolled seizure, dementia
- Any patient with a potentially curable malignancy who has not yet received appropriate standard therapies
- Anti seizure drugs known inducers of cytochrome P450
- Documented HIV, active hepatitis B or C infections
- Patients with active or uncontrolled infections or with serious illnesses or medical conditions, which would not permit the patient to be managed according to protocol
- Pregnant or lactating women; both men and women enrolled on study should be using adequate birth control measures throughout the course of the study. Women of childbearing potential must have a negative serum or urine pregnancy test documented within 14 days prior to registration and at study start
- Inability or refusal to practice contraception during therapy of ECO-4601, unless patient is surgically sterile or woman is postmenopausal for at least 2 years
- Patients who have been treated with any investigational drug within 4 weeks of patient's signature of informed consent form, or who are receiving concurrent treatment with other experimental drugs or anti cancer therapy
- Patients in whom a proper central line cannot be established
- Concomitant therapy with therapeutic coumadin; patients can be transferred to low molecular weight heparin
- Patients on low molecular weight heparin for < 2 weeks prior to ICF signature
- Polysorbate 80 being a major constituent of ECO-4601 and known to cause hypotension, patients with uncontrolled hypotension will be excluded
- Known hypersensitivity to farnesylated dibenzodiazepinone or any of the formulation components
Concomitant Therapy Permitted:
- Patients may receive ongoing supportive and palliative care (eg: pain control) as clinically indicated throughout the study.
- Patients can be treated with corticosteroids if medically needed
- Usage of low molecular weight heparin is allowed
- Anti seizure products are permitted provided they are not inducers of cytochrome P450.
Concomitant Therapy Not Permitted:
- Other anticancer treatment
- Other investigational therapy
- Concomitant therapy with coumadin
- Cytochrome enzyme inducing anti epileptics
- G-CSF, GM-CSF and other growth factors may not be used as a substitute for a scheduled dose reduction; however they may be used in the management of acute toxicity such as febrile neutropenia when clinically indicated at the discretion of the investigator. Use of erythropoietin is allowed if treatment has been initiated for ≥ 2 months. Use of growth factors must be documented on case report forms.
- Hormonal therapy
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: ECO-4601
|
Continuous IV infusion for 14 days with 7 days recovery (21 day cycle)
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
---|
Safety/tolerability of ECO-4601
|
Determination of MTD of ECO-4601
|
Determination of recommended dose for future studies of ECO-4601
|
Sekundære resultatmål
Resultatmål |
---|
Pharmacokinetics of ECO-4601
|
Safety of multiple cycles of administration of ECO-4601
|
Documentation of ECO-4601 antitumor activity as per RECIST criteria
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Petr Kavan, MD, Ph.D., Sir Mortimer B. Davis - Jewish General Hospital
- Ledende efterforsker: Benoît Samson, MD, Hopital Charles LeMoyne
- Studiestol: Gerald Batist, MD, Sir Mortimer B. Davis - Jewish General Hospital
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. februar 2006
Primær færdiggørelse (Faktiske)
1. august 2007
Studieafslutning (Faktiske)
1. august 2007
Datoer for studieregistrering
Først indsendt
15. juni 2006
Først indsendt, der opfyldte QC-kriterier
16. juni 2006
Først opslået (Skøn)
20. juni 2006
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
15. juli 2008
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
10. juli 2008
Sidst verificeret
1. juli 2008
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
- ECO-4601-101
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Gliom
-
University of OxfordImperial College Healthcare NHS Trust; Efficacy and Mechanism Evaluation...RekrutteringGlioma Glioblastoma MultiformeDet Forenede Kongerige
-
University College, LondonRekrutteringDiffus Midline Glioma, H3 K27M-MutantDet Forenede Kongerige
-
Goethe UniversityRekruttering
-
Giselle ShollerPhoenix Children's HospitalAfsluttetPontine GliomaForenede Stater
-
Genetron HealthHuashan Hospital; West China Hospital; The First Hospital of Jilin University og andre samarbejdspartnereAfsluttetGliom, ondartet | Glioma, blandetKina
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...RekrutteringGliom | Glioblastom | Glioma Glioblastoma MultiformeItalien
-
University of California, San FranciscoParker Institute for Cancer Immunotherapy; The V Foundation; Alliance for...RekrutteringDiffus Midline Glioma, H3 K27M-MutantForenede Stater
-
Mayo ClinicNational Cancer Institute (NCI)RekrutteringDiffus Midline Glioma, H3 K27M-MutantForenede Stater
-
Medical University of WarsawAfsluttetGliom, ondartet | Glioma Glioblastoma MultiformePolen
-
Ali NabavizadehBlue Earth DiagnosticsAfsluttetGlioma Glioblastoma MultiformeForenede Stater
Kliniske forsøg med ECO-4601
-
Thallion PharmaceuticalsAfsluttetGlioblastoma MultiformeForenede Stater, Canada
-
University Medicine GreifswaldIkke rekrutterer endnuSmerter, AkutTyskland
-
Velico MedicalAfsluttet
-
Charles MillerEspiner Medical LTDAfsluttet
-
Instituto de Investigacion Sanitaria La FeCharite University, Berlin, Germany; Imperial College London; Instituto de... og andre samarbejdspartnereRekrutteringGynækologisk kræft | Anastomotisk lækage | Cytoreduktiv kirurgiSpanien
-
University of California, Los AngelesAfsluttet
-
UNC Lineberger Comprehensive Cancer CenterThe Duke EndowmentRekruttering
-
Centre hospitalier de Ville-Evrard, FranceRekrutteringManiodepressivFrankrig
-
University of British ColumbiaThe Lawson FoundationAfsluttet
-
University of British ColumbiaGovernment of CanadaRekruttering